When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Part 1 – Case Presentation & Debate Setup D. Ross Camidge, MD, PhD, and Erin Schenk, MD, PhD, medical oncologists at the University of Colorado Cancer Center, discuss…
Part 2 – Case Discussion & Debate D. Ross Camidge, MD, PhD, and Erin Schenk, MD, PhD, medical oncologists at the University of Colorado Cancer Center, discuss the…
For their 2021 Future of Healthcare & Medicine conference, the MIT Club of Northern California invited founders, technologists, investors, and industry leaders who are working to build the…
Panelists discuss the progress and partnerships made by pharmaceutical companies, government, academia, and investors in the fight to control and end the pandemic, and offer ideas on how…
Members of the MIT Club of Northern California kickoff the 2021 Future of Healthcare conference in this panel discussion featuring speakers: Noubar Afeyan – Founder & CEO of…
A discussion of the science, psychology, design, and evaluation of motivating healthy behaviors on digital health platforms. Presenters: Baktash Ahadi – Co-founder & CEO of Taleem Julia Hu…
Subject matter experts discuss how AI can aid healthcare professionals in the diagnosis and prevention of disease through machine learning applications for medical imaging. Presenters: Darwin Ling –…
